Intellia Therapeutics
Filed with the SEC on · accession 0001193125-26-460948
NTLA filed a 8-K (current report) with the SEC on Nov 13, 2026. Intellia Therapeutics filed an 8-K/A to correct the item number on its prior 8-K, changing it from Item 2.02 to Item 7.01. The stock moved -8.1% by the first close after the filing.
Intellia Therapeutics filed an 8-K/A to correct the item number on its prior 8-K, changing it from Item 2.02 to Item 7.01. The original filing disclosed an investor webcast presentation titled 'Readying Lonvo-z for Patients with HAE.'
Close before
$10.55
Nov 12, 2026
First close after
-8.06%
$9.70
5 trading days
—
Since filing
—
✦ Ask GOAX AI about this filing — what it means for NTLA, what changed since its last filings and what to watch next.
Try it free for 7 days🔔 Want to stay updated on new SEC filings for NTLA?
Click hereNTLA filed a 8-K (SEC filing). Intellia Therapeutics filed an 8-K/A to correct the item number on its prior 8-K, changing it from Item 2.02 to Item 7.01. The original filing disclosed an investor webcast presentation titled 'Readying Lonvo-z for Patients with HAE.'
A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more. The "Item" number tells you the topic (e.g. 2.02 results, 5.02 executive change, 1.01 new agreement, 1.03 bankruptcy). Exhibits (99.1 press release) usually hold the details.
Public companies must tell the SEC about anything that can change their value — results, leadership changes, big deals, new shares, bankruptcy. Filings are the official source, often before the news. A 8-K (current report): A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more.
NTLA closed at $10.55 before the filing and $9.70 on Nov 13, 2026 (-8.06%).
Get alerts when NTLA files with the SEC, plus live charts, key levels and news for 13,000+ stocks.
Try SEPT free for 7 days